Topic Proposal Form for New ASH Clinical Practice Guidelines

# Instructions

ASH members are invited to use this form to propose a topic for new ASH-developed clinical practice guidelines. Proposed topics are reviewed by the ASH Committee on Quality (COQ). When prioritizing topics, the committee considers the following:

* Is the guideline topic important for hematologists (e.g., because of disease prevalence, impact of the disease on patients, high resource use or other factors)?
* Would guidelines address uncertainty regarding optimal practice or unexplained variation in clinical practice?
* Would guidelines address an underserved population or under-recognized health problem, i.e., potentially change clinical practice in ways that would improve health equity?
* Is there published evidence to inform the proposed guideline (not necessarily randomized controlled trials)?
* Is the topic adequately addressed by existing guidelines, and/or has the evidence base evolved since the publication of prior guidelines?
* Does the topic have strategic importance for the society’s mission?
* Would guidelines present the opportunity to synergize with other strategic initiatives within the society?

This form captures basic information needed by the committee to evaluate the suitability of the topic for ASH guidelines. If reviewed and approved by the Committee on Quality, the new project and associated budget must then be approved by the ASH Executive Committee.

The timeline for guideline development will depend on many factors including scope, availability of ASH resources to support the project, availability and enthusiasm of volunteer experts, and availability of individuals or an institution to conduct the systematic evidence review. Typically, ASH guidelines are planned to be completed within 18 months to two years. Rapid ASH guidelines on urgent clinical problems are also possible.

Non-ASH members who wish to propose a topic must team with a current ASH member.

Please email your completed topic nomination form to guidelines@hematology.org.

ASH will publish the title, abstract, and all authors of all proposals received on the ASH website.

Proposal to Develop New ASH Clinical Practice Guidelines

# Abstract

|  |  |
| --- | --- |
| Topic: |       |
| Correspondingauthor: |       |
| Other authors: |       |
| Sponsoring ASH committee, if applicable: |       |
| Submission date: |       |
| Resubmission date, if applicable: |       |
|  |

Describe your proposed topic in <250 words, including the primary clinical question(s) to be addressed by guidelines. You may find it useful to complete the remainder of this form first:

# Author Information

1. Contact information for corresponding author (institution, email):
2. If ASH undertakes development of a guideline on this topic, would you be interested in serving on the guideline panel? (Yes/No)
3. I understand that if this proposal moves forward, ASH leadership must approve all individuals to serve on the guideline panel. (Yes/No)
4. I understand that if selected for an ASH guideline panel, I must abide by ASH policies including with respect to conflict of interest, confidentiality, and publication. The policies are available from ASH on request.) (Yes/No)
5. I understand that if this proposal moves forward, ASH staff and leadership will determine an appropriate schedule and budget to which all involved must adhere. (Yes/No)
6. Are you an employee of a for-profit healthcare company that markets products that could be affected by guidelines on this topic?
7. Are you leading research relevant to this guideline topic? (Yes/No) If yes, please describe.
8. Have you been an author on previous guidelines on the same topic?

# Scope

1. Describe the disease or condition to be addressed by guidelines. Consider if the scope could be limited to subtypes of the disease or risk groups:
2. Which age group would be addressed? (Check all that apply.)

[ ] Infants [ ] Children and adolescents [ ] Adults [ ] Elderly adults

1. If applicable, describe other special populations or subgroups to be addressed, e.g., pregnant women, patients with co-occurring conditions:
2. If applicable, describe populations that should be excluded from the scope and explain why:
3. Are the described populations with this disease or condition seen or treated by hematologists? Consider both U.S. and international settings. If possible, provide references.
4. Which aspect of clinical care is to be addressed by guidelines? (Check all that apply.)

[ ]  Screening

[ ]  Prophylaxis

[ ]  Diagnosis

[ ]  Treatment

[ ]  Management of adverse effects

[ ]  Other:

# Rationale for ASH Guidelines

1. With respect to the ASH priority-setting considerations described within the instructions above, please suggest a rationale for ASH to address this topic with guidelines:

# Other Available Guidelines on This Topic

1. Please conduct a search for and list other guidelines available on this topic. Include title, year of publication, sponsoring organization, and URL. Your search may include Google, MEDLINE, the ECRI Trust, and the Guidelines International Network library. Specific organizations to search may include the British Committee for Standards in Haematology, other U.S. medical specialty societies, disease-specific societies, and the National Comprehensive Cancer Network.
2. How will new guidelines by ASH complement existing guidelines? Consider the clinical utility of existing guidelines (setting, scope, format), their quality (rigor of methodology, transparency, currency), and the credibility of the authors and sponsoring organization. Note: the Committee on Quality may determine that it is in ASH’s best interests to endorse an existing guideline.
3. Share any knowledge you have of plans by other organizations to maintain any existing guidelines or develop new guidelines on this topic: